Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems

Abstract

PURPOSE: The financial toxicity of cancer care is a source of significant distress for patients with cancer. The purpose of this study is to understand factors associated with financial toxicity in three distinct care systems. METHODS: We conducted a cross-sectional survey of patients in three care systems, Stanford Cancer Institute (SCI), VA Palo Alto Health Care System (VAPAHCS), and Santa Clara Valley Medical Center (SCVMC), from October 2017 to May 2019. We assessed demographic factors, employment status, and out-of-pocket costs (OOPCs) and administered the validated COmprehensive Score for financial Toxicity tool. We calculated descriptive statistics and conducted linear regression models to analyze factors associated with financial toxicity. RESULTS: Four hundred forty-four of 578 patients (77%) completed the entire COmprehensive Score for financial Toxicity tool and were included in the analysis. Most respondents at SCI were White, with annual household income (AHI) > $50,000 USD and Medicare insurance. At the VAPAHCS, most were White, with AHI ≤ $50,000 USD and insured by the Veterans Administration. At SCVMC, most were Asian and/or Pacific Islander, with AHI ≤ $25,000 USD and Medicaid insurance. Low AHI ( P < .0001), high OOPCs ( P = .003), and employment changes as a result of cancer diagnosis ( P < .0001) were associated with financial toxicity in the pooled analysis. There was variation in factors associated with financial toxicity by site, with employment changes significant at SCI, OOPCs at SCVMC, and no significant factors at the VAPAHCS. CONCLUSION: Low AHI, high OOPCs, and employment changes contribute to financial toxicity; however, there are variations based on site of care. Future studies should tailor financial toxicity interventions within care delivery systems.

The Association Between Cost-Related Non-Adherence Behaviors and Diabetes Outcomes

“…Although it is well established that a cancer diagnosis creates significant financial toxicities for patient and their families [25][26][27] , we found that participants were 3 times more likely to engage in diabetes-related CRN compared with cancer-related CRN. Participants who reported cancer-related CRN reported higher rates of delaying or forgoing not seeing an oncologist due to cost compared with other cancer-related CRN behaviors.…”

Cancer incidence in immunocompromised patients: a single-center cohort study

“…Cancer remains the second most costly disease among Americans with a 27% rise in cost within the past 10 years [ 2 – 4 ]. The annual costs of cancer care are estimated to exceed $245 billion dollars by 2030 [ 5 – 7 ]. Delays in cancer detection can lead to decreased functional outcomes, productivity loss, treatment complications, reduced health-related quality of life, and increased healthcare costs [ 8 ].…”

Improving supportive care for patients with Thoracic Malignancies – A randomized controlled trial

“…Despite the Veterans Health Administration serving as America's largest integrated health clinic, providing Veterans with equal access to healthcare, many Veterans remain at risk of poorer outcomes from lung cancer due to multi-level barriers. These barriers include complex comorbidities, psychosocial concerns, poor social support, severe complications from social determinants of health such as food and housing insecurity [ 3 ], and limited transportation [ 4 ], that impact Veterans' ability to engage fully in their care after a diagnosis of cancer [ [5] , [6] , [7] , [8] , [9] ].…”